通过PPAR-γ激动剂开发罗斯马林酸治疗胰岛素耐药性的实验和计算方法
Haritha Harindranath1, Aishwarya Susil1, S Rajeshwari1
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570 015, Karnataka, India.
Fitoterapia
|September 1, 2025
概括
迷香中的迷酸 (RA) 通过激活PPAR-γ,增强葡萄糖吸收和降低脂质,具有强大的抗糖尿病作用. 这种天然化合物为治疗糖尿病提供了有前途的治疗途径.
科学领域:
- 药理学和植物化学
- 分子生物学
- 计算化学
背景情况:
- 植物有很多好处,制药研究越来越多地探索它们的生物特性.
- 迷香是一种富含植物成分的草药,正在研究其治疗糖尿病 (DM) 的潜力.
- 迷香酸 (RA) 是迷香中的一个关键化合物,研究其治疗机制.
研究的目的:
- 研究罗斯马林酸 (RA) 和其化衍生物 (RAD) 的抗糖尿病机制.
- 通过PPAR-γ激动症阐明RA在糖尿病治疗中的作用.
- 用生物测试验证体检测结果.
主要方法:
- 使用IR,NMR,LC-MS/MS进行RA和RAD的提取,分离,净化和结构性表征.
- 在分子对接和分子动力学 (MD) 模拟中评估对PPAR-γ的结合亲和力.
- 在体外测定包括葡萄糖吸收,降脂效应,TR-FRET蛋白结合和GLUT-4表达.
主要成果:
- 无论是RA还是RAD都与PPAR-γ结合,RA具有较高的结合亲和力.
- 与RAD相比,RA表现出显著的抗糖尿病作用:葡萄糖吸收率降低了65%,脂质减少了71%.
- 与RAD (51. 83%) 相比,RA显示GLUT-4表达的增强,与皮奥格利塔相似.
结论:
- 罗斯马林酸 (RA) 作为PPAR-γ激动剂,提供一种可行的抗糖尿病作用机制.
- 在RA中,自由基对其优越的结合亲和力和治疗效果至关重要.
- 在治疗糖尿病 (DM) 方面, RA 是一种有前途的天然治疗药物.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252


